Monographie - Docetaxel

Senaste uppdateringen :
29/10/2024

Docetaxel

Molekylstruktur

Varunamn

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Adenex	Colombia
Asodocel	Argentina
Axogen	Chile
Bagotaxel	Chile
Bendadocel	Tyskland
Brecasta	Chile
Celtere	Peru
Daxotel	Chile, Colombia, Egypten, Malaysia
Doce NC	Tyskland
Docefrez	Förenta Staterna, Indien
Docekebir	Argentina
Docetax	Iran, Venezuela
Docetaxin	Tyskland
Docewin	Marocko
Dolectran	Argentina
Donataxel	Argentina, Ecuador, Peru
Doxel	Turkiet, Venezuela
Doxetal	Argentina
Doxitax	Turkiet
Oncodocel	Colombia, Peru
Onkotaxel	Colombia, Österrike
Ribodocel	Tyskland
Santax	Turkiet
Tadocel	Turkiet
Taxceus	Storbritannien
Taxotan	Tyskland
Taxotere	Argentina, Australien, Belgien, Chile, Colombia, Danmark, Ecuador, Egypten, Finland, Förenade Arabemiraten, Förenta Staterna, Frankrike, Grekland, Iran, Island, Italien, Japan, Kanada, Kroatien, Luxemburg, Malaysia, Marocko, Mexiko, Nederländerna, Norge, nya Zeeland, Österrike, Polen, Portugal, Rumänien, Saudi-Arabien, Schweiz, Spanien, Storbritannien, Sverige, Thailand, Tunisien, Turkiet, Tyskland, Ungern, Venezuela
Texot	Argentina
Tolnexa	Rumänien
Zenotere	Indien, Peru

Hänvisningar : Docetaxel

	Typ	Publikation
140	tidningen	Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993 ; 50: 1405-1409.
250	tidningen	Mazzo DJ, Nguyen-Huu JJ, Pagniez S, Denis P. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm 1997 ; 54: 566-569.
251	tidningen	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
1423	tidningen	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1660	tidningen	Thiesen J, Krämer I. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. Pharm World Sci 1999 ; 21: 137-141.
1662	tidningen	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1754	tidningen	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1940	tidningen	Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1953	tidningen	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	tidningen	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2175	tidningen	Dalle M, Sautou-Miranda V, Balayssac D, Bourlon S, Bagel S, Chopineau J. Peut-on conditionner les solutions de docétaxel dans des poches en PVC ? J Pharm Clin 2006 ; 25, 3: 147-152.
2210	tidningen	Walker S.E, Charbonneau F, Law S. Stability of Docetaxel Solution after Dilution in Ethanol and Storage in Vials and after Dilution in Normal Saline and Storage in Bags. Can J Hosp Pharm 2007 ; 60, 4: 231-237.
2262	tidningen	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2341	affisch	Bourlon S, Sautou-Miranda V, Dalle M. Release of di(2-ethylhexyl)phtalate from polyvinylchloride bags during docetaxel infusions Poster ESCP Stockholm May 2005
3130	Laboratorium	Docétaxel (Taxotere®) – Résumé des caractéristiques du produits Sanofi Avantis France 2009
3163	tidningen	Acott SR, Hart M. Physical and chemical stability of Taxotere 1-vial 20mg/mL infusion solution following refrigerated storage. EJHP 2010 ; 16, 5: 26-28.
3195	tidningen	MacLeod S, Sewell G. Physical and chemical stability of docetaxel infusions. EJHP 2011 ; 17, 2: 39-43.
3215	tidningen	Hart MC, Ahmed W. Taxotere 1-vial (docetaxel 20 mg/ml) physical and chemical stability over 28 days in infusion bags containing 0.9% saline solution and 5% glucose solution. EJOP 2011 ; 5,1: 24-27.
3277	tidningen	Yang Z, Cameron S, Paul H. Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration. Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3804	tidningen	Lazzarini R, Salvadori S, Trapella C, Guerrini R, Marzola E, Pasini G, Dalpiaz A. Physicochemical stability of cabazitaxel and docetaxel solutions. EJHP 2014 ;22:150-155.
3937	tidningen	Park K.H, Chung D.J. Stability study of docetaxel solution (0.9% saline) using Non-PVC and PVC tubes for intravenous administration. Biomat Res 2015 ; 19, 2

Mentions Légales